207 related articles for article (PubMed ID: 24638009)
1. Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.
Potosky AL; Haque R; Cassidy-Bushrow AE; Ulcickas Yood M; Jiang M; Tsai HT; Luta G; Keating NL; Smith MR; Van Den Eeden SK
J Clin Oncol; 2014 May; 32(13):1324-30. PubMed ID: 24638009
[TBL] [Abstract][Full Text] [Related]
2. Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer.
Sammon JD; Abdollah F; Reznor G; Pucheril D; Choueiri TK; Hu JC; Kim SP; Schmid M; Sood A; Sun M; Kibel AS; Nguyen PL; Menon M; Trinh QD
Eur Urol; 2015 Jul; 68(1):32-9. PubMed ID: 25457017
[TBL] [Abstract][Full Text] [Related]
3. Survival following primary androgen deprivation therapy among men with localized prostate cancer.
Lu-Yao GL; Albertsen PC; Moore DF; Shih W; Lin Y; DiPaola RS; Yao SL
JAMA; 2008 Jul; 300(2):173-81. PubMed ID: 18612114
[TBL] [Abstract][Full Text] [Related]
4. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
5. Primary androgen deprivation therapy as monotherapy in unfavourable intermediate- and high-risk localised prostate cancer: a Singaporean single-centre perspective.
Lee HJ; Lee A; Huang HH; Lau WKO
Int Urol Nephrol; 2018 Apr; 50(4):665-673. PubMed ID: 29492797
[TBL] [Abstract][Full Text] [Related]
6. Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer.
Dell'Oglio P; Bishr M; Boehm K; Trudeau V; Larcher A; Tian Z; Sosa J; Moschini M; Saad F; Capitanio U; Briganti A; Graefen M; Montorsi F; Karakiewicz PI
Eur Urol Focus; 2018 Dec; 4(6):834-841. PubMed ID: 28753853
[TBL] [Abstract][Full Text] [Related]
7. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
Fu AZ; Tsai HT; Haque R; Yood MU; Cassidy-Bushrow AE; Van Den Eeden SK; Keating NL; Smith MR; Zhou Y; Aaronson DS; Potosky AL
J Urol; 2017 Jun; 197(6):1448-1454. PubMed ID: 28007467
[TBL] [Abstract][Full Text] [Related]
8. The role of primary androgen deprivation therapy in localized prostate cancer.
Wong YN; Freedland SJ; Egleston B; Vapiwala N; Uzzo R; Armstrong K
Eur Urol; 2009 Oct; 56(4):609-16. PubMed ID: 19368995
[TBL] [Abstract][Full Text] [Related]
9. Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer.
Hori S; Jabbar T; Kachroo N; Vasconcelos JC; Robson CN; Gnanapragasam VJ
J Cancer Res Clin Oncol; 2011 Feb; 137(2):235-41. PubMed ID: 20390426
[TBL] [Abstract][Full Text] [Related]
10. Radical prostatectomy for clinically localized prostate cancer in patients aged 75 years or older: comparison with primary androgen deprivation therapy.
Ryu JH; Kim SJ; Kim YB; Jung TY; Ko WJ; Kim SI; Kim DY; Oh TH; Moon KT; Cho HJ; Cho JM; Yoo TK
Aging Male; 2018 Mar; 21(1):17-23. PubMed ID: 28828908
[TBL] [Abstract][Full Text] [Related]
11. Is Primary Androgen Deprivation Therapy a Suitable Option for Asian Patients With Prostate Cancer Compared With Radical Prostatectomy?
Ha US; Choi JB; Shim JI; Kang M; Park E; Kang S; Park J; Yang J; Choi I; Ahn J; Kwak C; Jeong CW; Kim CS; Byun SS; Seo SI; Lee HM; Lee SJ; Lee SH; Chung BH; Lee JY
J Natl Compr Canc Netw; 2019 May; 17(5):441-449. PubMed ID: 31085754
[TBL] [Abstract][Full Text] [Related]
12. National practice patterns and time trends in androgen ablation for localized prostate cancer.
Cooperberg MR; Grossfeld GD; Lubeck DP; Carroll PR
J Natl Cancer Inst; 2003 Jul; 95(13):981-9. PubMed ID: 12837834
[TBL] [Abstract][Full Text] [Related]
13. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
14. Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer.
Fu AZ; Tsai HT; Haque R; Ulcickas Yood M; Van Den Eeden SK; Cassidy-Bushrow AE; Zhou Y; Keating NL; Smith MR; Aaronson DS; Potosky AL
World J Urol; 2016 Dec; 34(12):1611-1619. PubMed ID: 27084777
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of androgen deprivation therapy in prolonging survival of older men treated for locoregional prostate cancer.
Holmes L; Chan W; Jiang Z; Du XL
Prostate Cancer Prostatic Dis; 2007; 10(4):388-95. PubMed ID: 17486111
[TBL] [Abstract][Full Text] [Related]
16. Patterns of androgen deprivation therapies among men diagnosed with localised prostate cancer: a population-based study.
Lycken M; Garmo H; Adolfsson J; Stattin P; Holmberg L; Bill-Axelson A
Eur J Cancer; 2014 Jul; 50(10):1789-1798. PubMed ID: 24736041
[TBL] [Abstract][Full Text] [Related]
17. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism.
Hu JC; Williams SB; O'Malley AJ; Smith MR; Nguyen PL; Keating NL
Eur Urol; 2012 Jun; 61(6):1119-28. PubMed ID: 22336376
[TBL] [Abstract][Full Text] [Related]
18. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy.
Cooperberg MR; Hinotsu S; Namiki M; Ito K; Broering J; Carroll PR; Akaza H
J Clin Oncol; 2009 Sep; 27(26):4306-13. PubMed ID: 19667269
[TBL] [Abstract][Full Text] [Related]
19. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
[TBL] [Abstract][Full Text] [Related]
20. Androgen-deprivation therapy versus radical prostatectomy as monotherapy among clinically localized prostate cancer patients.
Liu J; Shi L; Sartor O; Culbertson R
Onco Targets Ther; 2013; 6():725-32. PubMed ID: 23836984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
